Pablo Corral: Is Inflammation Really a Therapeutic Target in Atherosclerosis
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Kevin Jon Williams, published in JIM, adding:
“Anti-inflammatory agents in atherosclerosis – and a need for reform: Extraordinary claims require extraordinary evidence
A provocative and timely Perspective by Kevin Jon Williams challenging the inflammatory hypothesis of atherosclerosis.
- ZEUS adds another null result: targeting inflammation did not translate into fewer cardiovascular events (HR approximately 0.99).
- Williams highlights a much broader issue: more than 50 clinical trials of anti-inflammatory strategies in atherosclerosis over decades have produced a remarkably disappointing clinical track record.
- His challenge to the field is uncomfortable but important: should inflammation continue to be considered a definitive therapeutic target in atherosclerosis when repeated clinical testing has failed to deliver consistent benefit?
- In sharp contrast, lowering cholesterol-rich ApoB-containing lipoproteins rests on extensive and reproducible evidence targeting the proven causal agents of atherosclerosis.
As evidence accumulates, are we witnessing regression to the mean – or regression to the truth?
Inflammation may be part of atherosclerosis – but being part of the disease does not make it a proven therapeutic target.”
Title: Anti-inflammatory agents in atherosclerosis – and a need for reform: Extraordinary claims require extraordinary evidence
Authors: Kevin Jon Williams

Other posts featuring Pablo Corral on Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments